Multiple Innovative Technologies & Platforms Empower Antibody Discovery

The development of antibody drugs has greatly depended on the establishment of new technologies and platforms, which are also the key factors that have led to the great success in the development of antibody drugs in the last three decades. Antibodies have become a pivotal role in the biopharmaceutical field, but antibody discovery has been constrained by a series of bottlenecks, such as time-consuming and inefficient screening process, poor tissue permeability, difficulties in modular application, and immunogenicity. This talk presents new solutions to these challenges through complete case studies, from antibody discovery to functional assays, antibody optimization, and up to application, using VHH antibody as an example. More case studies will show how new technologies and platforms can be applied to solve common problems in antibody discovery.
Speaker: Dr. Long Xu
Dr. Long Xu received his Bachelor's degree at Nanjing University in China, and his PhD degree at Boston University in the United States. Dr. Xu worked at Washington University in St. Louis, Lighting Research Center and other internationally renowned institutions for more than 10 years, engaging in research in life sciences and health, covering a variety of areas including DNA damage and repair, protein isolation and identification, DNA photoproducts, lighting and health, etc. In 2022, Dr. Xu joined Biointron, focusing on the establishment of a variety of high-throughput innovative antibody technology platforms, and dedicated to the discovery, optimization and application of antibodies.

[@adebowalealade4648]

Very informative!

[@antibodysociety]

Thank you for watching!